To a stirred solution of methyl 2-(5-fluoro-2-nitrophenyl)acetate(790 mg, 3 mmol) and 2-methyl-5-nitrophenol (700 mg, 4.5 mmol) in 2 mL of DMSO was added K 2 CO 3 (830 mg, 6 mmol). The reaction mixture was allowed to stand for 1 hour at 100 o C, and then cooled to RT. The mixture was acidified with 1N HCl solution and extracted with ethyl acetate, the organic phase was washed with water and brine, dried over sodium sulfate, concentrated and purified with column chromatography (hexane : ethyl acetate 3:1). 830 mg (80%) of 1 was obtained. 1 To a stirred solution of compound 1(690 mg, 2 mmol) in 30 mL of ethyl acetate and 3 mL of ethanol was added tin chloride dihydrate (2.26 g, 10 mmol). The reaction mixture was allowed to stand for 4~5 hours at 80 o C, and then cooled to RT. The mixture was eluted with ethyl acetate and added saturated sodium bicarbonate solution, and stirred for 15 min, the organic phase was separated and washed with water and brine, concentrated and purified with column chromatography (dichloromethane : methanol 15:1). 380 mg (75%) of 2 was obtained. 1 H NMR (600 MHz, CD 3 OD) δ 6.97 (d, J = 8.4 Hz, 1H), 6 .87 (d, J = 2.4 Hz, 1H), 6 .83 (d, J = 8.4 Hz, 1H), 6 .78 (dd, J = 9.0, 2.4 Hz, 1H), 6 .44 (dd, J = 7.8, 2.4, 1H), 6 .24 (d, J = 2.4, 1H), 3 
.50 (s, 2H), 2.09 (s, 3H). MS (ESI) m/z 255 (M+H)
+ .
To a stirred solution of compound 2(254 mg, 1 mmol) in 7 mL of acetonitrile was added DIEA (530 uL, 3 mmol). The reaction mixture was then cooled to -35 o C, and added the acyl chloride 3 (310 mg, 1.2 mmol) dropwise. After the addition was finished, the mixture was allowed to return to room temperature in half an hour, then was added 1-ethylpiperazine (270 uL, 2 mmol) and stirred overnight. The mixture was eluted with ethyl acetate and washed with water and brine, and the organic phase was collected and dried over sodium sulfate, concentrated and purified with column chromatography (dichloromethane : methanol 15:1). 380 mg (69%) of TL4-44 was obtained as white solid. 1 Ethyl acetate/Hexane) as an eluent to afford title compound (380 mg, 77% yield). Rt = 
4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo

4-((4-ethylpiperazin-1-yl)methyl)-N-(3-((4-methoxy-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino)-4-methylphenyl)-3-(trifluoromethyl)benzamide
To a solution of 4-methoxy- 
4-((4-ethylpiperazin-1-yl)methyl)-N-(3-((4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino)-4-methylphenyl)-3-(trifluoromethyl)benzamide
To a solution of 4-((4-ethylpiperazin-1-yl)methyl)-N-(3-((4-methoxy-1-((2- (trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino)-4- methylphenyl)-3-(trifluoromethyl)
Protein expression and purification
The kinase domain of DDR1 (Uniprot Q08345, residues 601-913) was cloned into the transfer vector pFB-LIC-Bse for baculoviral expression in Sf9 insect cells. Some 72
hours post infection, cells were harvested and lysed using a C5 high pressure homogenizer (Emulsiflex). DDR1 protein was purified initially by Ni-affinity chromatography buffered in 50 mM HEPES pH 7.5, 500 mMNaCl, 5% glycerol, 5 mM
Imidazole, 1 mM TCEP supplemented with protease inhibitor cocktail set III (Calbiochem) at 1:1000 dilution. Protein was eluted with imidazole and the hexahistidine tag cleaved using TEV protease. DDR1 was further purified by size exclusion chromatography and the final buffer adjusted to 10 mM HEPES pH 7.5, 250 mMNaCl, 5% glycerol, 1 mM TCEP, 2 mM DTT, 5 mM L-arginine, 5 mM L-glutamate.
Crystallization and structure determination
DDR1 was co-crystallized with inhibitor at 20°C in 150 nL sitting drops mixing 50 nL protein solution at 8.5 mg/mL with 100 nL of a reservoir solution containing 0.1 M bis-tris propane pH 7.2, 21%(w/v) PEG 3350 and 0.1 M sodium/potassium phosphate. On mounting crystals were cryo-protected with an additional 25% ethylene glycol. Diffraction data were collected at 100 K on Diamond Light Source beamline I02.
Crystals belonged to the tetragonal space group P4 1 2 1 2 with unit-cell parameters a=59 Å b=59 Å c=178 Å, α=90° β=90° γ=90°. One molecule was present in the asymmetric unit. 
General procedure for the EC 50 test
Tet inducible human DDR1 over-expressing U2OS was used for the EC 50 test. DDR1
was induced by 2 µg/ml doxycycline for 48 hrs prior to DDR1 activation by rat tail collagen I. The DDR1 over-expressed U2OS was pre-treated by media containing each concentration of the compound for 1 hr and treated by changing the media to the EC 50 test media containing 10 µg/ml collagen and each concentration of the compound for 2 hrs. Each cells was washed with cold PBS three times and lysed with the lysis buffer (50 mMTris, pH 7.5, 1% Triton X-100, 0.1% SDS, 150 mMNaCl, 5 mM EDTA, 100 mMNaF, 2 mM Na3VO4, 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin).
The activation of DDR1 was quantified by density using program ImageJ to determine EC 50 following Western blot using anti-activated human DDR1b (Y513).
General procedure for generating the G707A mutation
Generation of the G707A DDR1 mutant by site-directed mutagenesis using PCR was performed using following primers: sense, 5΄ CCTCTGCATGATTACTGACTACATGGAGAACGCCGACCTCAACCA 3΄ and antisense, 5΄ CTGGTGGGCACTGAGGAACTGGTTGAGGTCGGCGTTCTCCATGT 3΄ to substitute Gly707 to Alanine (G707A). The changed DNA bases were confirmed by DNA sequencing.
Combinatorial screening
Kinase Inhibitor Focused Library (LINCS)
A Kinase Inhibitor Focused Library (LINCS) was chosen for screening to identify single agents with little-to-no appreciable efficacy but that are able to synergize with 
Drug combination studies
For drug combination studies performed as validation of results generated in the LINCS library screen, single agents were added simultaneously at fixed ratios to SNU1040 cells. Cell 
